Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4278

Sort by

Sort Order Select

Journal Articles

The journey of a thousand miles begins with 1 step

Luca Malcovati

Blood (2021) 138 (10): 824–826.

https://doi.org/10.1182/blood.2021012304

Published: 2021

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Deletion 17p: a matter of size and number?

Sonja Zweegman, Niels W. C. J. van de Donk

Blood (2021) 137 (9): 1135–1136.

https://doi.org/10.1182/blood.2020009102

Published: 2021

Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood (2020) 136 (8): 936–945.

https://doi.org/10.1182/blood.2020005288

Published: 2020

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Christian Winther Eskelund, Simon Husby, Francesco Favero, Tobias Wirenfeldt Klausen, Francisco German Rodriguez-Gonzalez, Arne Kolstad, Lone Bredo Pedersen, Riikka Katariina Räty, Christian H. Geisler, Mats Jerkeman, Joachim Weischenfeldt, Kirsten Grønbæk

Blood (2020) 135 (22): 2000–2004.

https://doi.org/10.1182/blood.2019003539

Published: 2020

Includes: Supplemental data

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2019) 134 (Supplement_1): 4579.

https://doi.org/10.1182/blood-2019-127723

Published: 2019

Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4374.

https://doi.org/10.1182/blood-2019-128041

Published: 2019

Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4435.

https://doi.org/10.1182/blood-2019-126104

Published: 2019

Journal Articles

Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection

Zac McDonald, PhD, Mariya Liyasova, PhD, Paul Taylor, Xin Xu, Kathleen Gorospe, Chenyu Yao, Qixin Liu, Liqiang Yang, PhD, Bin Ma, PhD, Jesus Piza, MD, Donna E Reece, MD, Suzanne Trudel, MD

Blood (2019) 134 (Supplement_1): 4347.

https://doi.org/10.1182/blood-2019-130251

Published: 2019

Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 501.

https://doi.org/10.1182/blood-2019-127509

Published: 2019

Journal Articles

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Nabin Karki, MBBS, Vamsi Kota, MBBS, Katherine Saunders, PharmD, Cara Iacobellis, PharmD, Anand Jillella, MD, Germame Ajebo, MD, Locke J. Bryan, MD

Blood (2019) 134 (Supplement_1): 5294.

https://doi.org/10.1182/blood-2019-129644

Published: 2019

Journal Articles

High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

Miguel Quintela, Iolanda Vieira, Cláudia Moreira, Sérgio Chacim, Nelson Domingues, Isabel Oliveira, Ana Espirito Santo, Maria Ilidia Moreira, Ângelo Martins, Maria Luisa Viterbo, Dulcineia Pereira, Jose Mario Mariz

Blood (2019) 134 (Supplement_1): 5356.

https://doi.org/10.1182/blood-2019-131254

Published: 2019

Journal Articles

Brentuximab Vedotin Plus Bendamustine: As Salvage Regimen for Relapsed or Refractory Hodgkin Lymphoma, King Abdulaziz Medical City - Jeddah - KSA Experience

Muteb Althomali, Ahmad Absi, Ihab El Hemaidi, Ashraf Warsi, Sameer AlAmoudi, Majed Alahmadi, Walaa Rajkhan, Sultan Almutairi, Saleem Eldadah, Manar Khalil, Muna Adam, Syed Adnaan Ali, Abdulrahman Alghamdi, Ahmad Alsaeed

Blood (2019) 134 (Supplement_1): 5295.

https://doi.org/10.1182/blood-2019-121993

Published: 2019

Journal Articles

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Blood (2019) 134 (Supplement_1): 5296.

https://doi.org/10.1182/blood-2019-121997

Published: 2019

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5378.

https://doi.org/10.1182/blood-2019-131028

Published: 2019

Journal Articles

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Shakira J. Grant, MBBS, Lindsay M. Hannan, MD MSPH, Jessica L. Brand, PhD, Robert E. Richard, MD PhD, Daniel Y. Wu, MD, Solomon A. Graf, MD, Jonathan Grim, MD PhD, Nicholas Burwick, MD, Thomas R. Chauncey, MD PhD

Blood (2019) 134 (Supplement_1): 5883.

https://doi.org/10.1182/blood-2019-122580

Published: 2019

Journal Articles

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Swami P. Iyer, MD, Sattva S Neelapu, MD, Ethan Burns, MD, Ranjit Nair, MBBS,MD, Chitra Hosing, MD, Yago Nieto, MD PhD, Jason R. Westin, MD, Simrit Parmar, MBBS, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Madeleine Duvic, MD, Roberto N. Miranda, MD, Hun Ju Lee, Felipe Samaniego, MD, Sairah Ahmed, MD, Feng Lei, MS, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 1546.

https://doi.org/10.1182/blood-2019-132278

Published: 2019

Journal Articles

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Blood (2019) 134 (Supplement_1): 1985.

https://doi.org/10.1182/blood-2019-122013

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The journey of a thousand miles begins with 1 step

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Deletion 17p: a matter of size and number?

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

AL patients don’t dare go without dara

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

Brentuximab Vedotin Plus Bendamustine: As Salvage Regimen for Relapsed or Refractory Hodgkin Lymphoma, King Abdulaziz Medical City - Jeddah - KSA Experience

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only